ekso bionics holdings inc - EKSO

EKSO

Close Chg Chg %
4.29 0.14 3.28%

Open Market

4.43

+0.14 (3.28%)

Volume: 82.93K

Last Updated:

Dec 8, 2025, 3:42 PM EDT

Company Overview: ekso bionics holdings inc - EKSO

EKSO Key Data

Open

$4.30

Day Range

4.10 - 4.50

52 Week Range

2.75 - 14.97

Market Cap

$14.55M

Shares Outstanding

3.39M

Public Float

3.13M

Beta

0.82

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$5.57

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

304.68K

 

EKSO Performance

1 Week
 
0.00%
 
1 Month
 
-8.14%
 
3 Months
 
12.01%
 
1 Year
 
-57.79%
 
5 Years
 
-94.45%
 

EKSO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About ekso bionics holdings inc - EKSO

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

EKSO At a Glance

Ekso Bionics Holdings, Inc.
101 Glacier Point
San Rafael, California 94901
Phone 1-510-984-1761 Revenue 17.93M
Industry Medical Specialties Net Income -11,330,000.00
Sector Health Technology Employees 61
Fiscal Year-end 12 / 2025
View SEC Filings

EKSO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.686
Price to Book Ratio 1.066
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.332
Enterprise Value to Sales 0.658
Total Debt to Enterprise Value 0.508

EKSO Efficiency

Revenue/Employee 293,852.459
Income Per Employee -185,737.705
Receivables Turnover 2.477
Total Asset Turnover 0.645

EKSO Liquidity

Current Ratio 2.50
Quick Ratio 1.894
Cash Ratio 0.861

EKSO Profitability

Gross Margin 57.132
Operating Margin -58.354
Pretax Margin -63.208
Net Margin -63.208
Return on Assets -40.777
Return on Equity -89.519
Return on Total Capital -60.621
Return on Invested Capital -64.423

EKSO Capital Structure

Total Debt to Total Equity 47.084
Total Debt to Total Capital 32.012
Total Debt to Total Assets 22.449
Long-Term Debt to Equity 33.887
Long-Term Debt to Total Capital 23.039
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ekso Bionics Holdings Inc - EKSO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
11.25M 12.91M 18.28M 17.93M
Sales Growth
+26.62% +14.81% +41.57% -1.94%
Cost of Goods Sold (COGS) incl D&A
4.19M 6.27M 8.58M 7.68M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
561.00K 887.00K 1.70M 1.61M
Depreciation
561.00K 864.00K 1.37M 1.30M
Amortization of Intangibles
- 23.00K 325.00K 312.00K
COGS Growth
+16.70% +49.61% +36.79% -10.45%
Gross Income
7.05M 6.64M 9.70M 10.24M
Gross Income Growth
+33.35% -5.87% +46.08% +5.60%
Gross Profit Margin
+62.72% +51.42% +53.06% +57.13%
2021 2022 2023 2024 5-year trend
SG&A Expense
20.58M 21.77M 24.19M 19.97M
Research & Development
2.75M 3.63M 5.03M 3.87M
Other SG&A
17.83M 18.14M 19.17M 16.10M
SGA Growth
+14.78% +5.80% +11.12% -17.44%
Other Operating Expense
304.00K 425.00K 619.00K 730.00K
Unusual Expense
(5.06M) (1.32M) 133.00K (365.00K)
EBIT after Unusual Expense
(8.77M) (14.24M) (15.25M) (10.10M)
Non Operating Income/Expense
(884.00K) (685.00K) 349.00K (966.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
113.00K 156.00K 302.00K 269.00K
Interest Expense Growth
-18.71% +38.05% +93.59% -10.93%
Gross Interest Expense
113.00K 156.00K 302.00K 269.00K
Interest Capitalized
- - - -
-
Pretax Income
(9.76M) (15.08M) (15.20M) (11.33M)
Pretax Income Growth
+38.30% -54.44% -0.78% +25.45%
Pretax Margin
-86.82% -116.79% -83.14% -63.21%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(9.76M) (15.08M) (15.20M) (11.33M)
Minority Interest Expense
- - - -
-
Net Income
(9.76M) (15.08M) (15.20M) (11.33M)
Net Income Growth
+38.30% -54.44% -0.78% +25.45%
Net Margin Growth
-86.82% -116.79% -83.14% -63.21%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(9.76M) (15.08M) (15.20M) (11.33M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(9.76M) (15.08M) (15.20M) (11.33M)
EPS (Basic)
-12.0119 -17.451 -16.4397 -8.4297
EPS (Basic) Growth
+63.75% -45.28% +5.80% +48.72%
Basic Shares Outstanding
812.87K 864.13K 924.47K 1.34M
EPS (Diluted)
-13.1955 -17.451 -16.4397 -8.4297
EPS (Diluted) Growth
+60.18% -32.25% +5.80% +48.72%
Diluted Shares Outstanding
817.93K 864.13K 924.47K 1.34M
EBITDA
(13.27M) (14.67M) (13.41M) (8.85M)
EBITDA Growth
-8.41% -10.57% +8.56% +34.01%
EBITDA Margin
-117.97% -113.61% -73.38% -49.38%

Snapshot

Average Recommendation BUY Average Target Price 9.50
Number of Ratings 2 Current Quarters Estimate -0.35
FY Report Date 12 / 2025 Current Year's Estimate -2.17
Last Quarter’s Earnings -0.54 Median PE on CY Estimate N/A
Year Ago Earnings -8.40 Next Fiscal Year Estimate -0.41
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate -0.35 -0.23 -2.17 -0.41
High Estimates -0.21 -0.03 -0.92 -0.10
Low Estimate -0.49 -0.43 -3.42 -0.72
Coefficient of Variance -56.57 -122.98 -81.46 -106.93

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Ekso Bionics Holdings Inc in the News